Biotech | April 20, 2022
MicroGEM granted EUA for Covid-19 PCR Saliva test
The MicroGEM Saliva test is the first point of care PCR saliva test for Covid-19 delivering results in minutes
The MicroGEM Saliva test is the first point of care PCR saliva test for Covid-19 delivering results in minutes
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
If authorized by the USFDA, the Proof Lab Test System may be used to deliver accurate, actionable, lab-quality results for Covid-19 in as little as 18 minutes
Makrolon polycarbonate is key to needle-free injections that can stand up to sterilization
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current USFDA approved or emergency use authorized-vaccines
Subscribe To Our Newsletter & Stay Updated
